Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy

Phase 2

Completed

• Conditions: Multiple System Atrophy
• Interventions: Biological: normal saline; Biological: autologous mesenchymal stem cells

• Registration Number: NCT00911365
• Lead Sponsor: Yonsei University

Brief Summary

This study is based on positive results in open label trial of mesenchymal stem cells therapy in patients with Multiple System Atrophy (MSA).

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05
• Study First Submitted: 2009-05-26
• Study First Submitted QC: 2009-05-29
• Study First Posted: 2009-06-01
• Primary Completion: 2011-06
• Study Completion: 2011-06
• Status Verified: 2011-07
• Last Update Submitted: 2011-08-02
• Last Update Posted: 2011-08-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• 75 Years Old or Less
• Multiple System Atrophy
• Voluntary Participants

Read More

Exclusion Criteria

• Doubted dementia (MMSE < 24)
• Severe febrile condition
• Serum SGOT/SGPT three times above
• Malignant mass

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
normal saline	normal saline	-
autologous mesenchymal stem cells	autologous mesenchymal stem cells	-

Primary Outcome Measures

Name	Time	Method
Scores on unified MSA rating scale	one month	The statistical difference between scores before and after autologous mesenchymal stem cells treatment of unified MSA rating scale will be measured every month and every year using paired t-test.

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of